Intrinsiqq
Axogen Inc. logo

Axogen Inc. Quality Score

AXGN

⊜ Compare
Quality61

Valuation is the primary weakness (avg 20/100). Growth is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-79.0x

Negative earnings, no valuation support

Cash Flow Multiple
40/100
139.2x

Above 30x, cash flow yield is thin

Revenue Growth
100/100
17.8%

Above 10% CAGR, strong compounder

Cash Flow Growth
100/100
292.0%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
0/100
46.2%

Heavy dilution above 5%

Margin Trend
100/100
+16.3pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$329M

Net cash position, no leverage concern

2022
$49.0M
$67.0M
2023
$31.0M
$69.0M
2024
$33.0M
$69.0M
2025
$42.0M
$68.0M
TTM
$348M
$19.0M
CashDebt
Return on Capital
0/100
-3.5%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Axogen (AXGN) quality: score, margins and returns

Axogen (AXGN) scores 61/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 7 metrics each scored 0 to 100, on -5.2% operating margins and -3.5% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Axogen (AXGN) a high-quality business?+

Axogen scores 61 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a -5.2% operating margin and a -3.5% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Axogen's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from AXGN's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Axogen scores well and where it falls behind.

What is Axogen's return on invested capital (ROIC)?+

Axogen earns about -3.5% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to AXGN's margins and growth on this scorecard to judge durability.

How profitable is Axogen?+

Axogen runs an operating margin of about -5.2% and a net margin of about -12.0%. Revenue has grown at roughly 14.9% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 26 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 29 Oct 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Electromedical & Electrotherapeutic Apparatus · Pick stocks to compare with AXGN

CompareIntrinsic value
INMDInMode Ltd.
$14.20+0.85%48
OMOutset Medical Inc.
$4.44+6.99%25
ZYXIQZynex Inc
No recent price20
BLFSBiolife Solutions Inc.
No recent price61
FONRFonar Corp
No recent price53
CBLLCeribell, Inc.
$27.39-3.11%25
VASOVaso Corporation
$0.29+0.00%37
ELMDElectromed Inc.
$28.01+4.83%75

Held by ETFs

AXGN is in 55 US ETFs. The largest of them, with AXGN's weight in each:

Spot a number that looks wrong? Check it in AXGN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AXGN

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.